Moderna(US:MRNA) 智通财经网·2025-07-10 13:45Group 1 - The U.S. regulatory agency has approved Moderna's COVID-19 vaccine for children under 12 at high risk, but the scope of eligibility has been narrowed compared to previous guidelines [1] - Under Robert F. Kennedy Jr.'s leadership, the U.S. health department has implemented measures to limit the use of COVID-19 vaccines for children, contrasting with the previous recommendation for vaccination for all individuals aged 6 months and older [1] - Public health experts express concerns that limiting vaccine access may pose risks to children under 2 years old, who are more susceptible to COVID-19 infection [1] Group 2 - Only 13% of children received the COVID-19 vaccine in the last quarter, which is half the vaccination rate of adults [2] - Over 150 children under 18 have died from COVID-19 in the year leading up to August 2024, indicating a serious risk for children [2] - Approximately 6 million American children may experience long-term effects from COVID-19, including an increased risk of developing type 2 diabetes [2] Group 3 - Moderna's stock price increased by over 3% in early trading [3]